NERV NERV
Company Profile ↓Company Overview
NERV (NERV) is a publicly traded company listed on with a market capitalization of $188.24M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of -0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +129.79% |
| 6 Months: | -11.76% |
| 3 Months: | -30.40% |
| 1 Month: | -8.81% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.81 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 46.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 0 | 41.18M | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.90M | 3.37M | 2.84M | 4.98M | 16.67M |
| Operating Income | -5.71M | -8.19M | -7.76M | -4.96M | -8.23M | -9.24M | -10.48M | -9.75M | -11.41M | -9.53M | -12.74M | -12.94M | -12.42M | -13.63M | -16.31M | -12.90M | -14.28M | -32.37M | -12.27M | 29.51M | -8.09M | -7.30M | -7.51M | -8.96M | -7.52M | -7.99M | -6.97M | -5.21M | -5.35M | -4.52M | -6.08M | -6.68M | -6.28M | -4.37M | - | -3.90M | -3.37M | -2.84M | -4.98M | -16.67M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.90M | -3.26M | -2.74M | -283.67M | -16.67M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.75M | -3.26M | -2.74M | -283.67M | -125.40M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.94M | -8.44M | -8.00M | -5.21M | -8.42M | -9.40M | -10.64M | -9.78M | -11.26M | 162.00K | -12.42M | -12.53M | -12.02M | -13.20M | -15.83M | -12.48M | -13.96M | -29.92M | -12.15M | 29.53M | -8.11M | -7.32M | -8.80M | -10.59M | -9.21M | -9.76M | -8.72M | -6.90M | -6.97M | -6.19M | -7.82M | -8.57M | -8.23M | 22.51M | - | -3.75M | -3.26M | -2.74M | -283.67M | -125.40M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.32 | -0.36 | - | - | 0.73 | -0.19 | - | - | -0.25 | -1.72 | -1.83 | -1.63 | -1.29 | -1.31 | -1.12 | -1.03 | -1.13 | -1.09 | 2.97 | - | -0.50 | -0.43 | -0.36 | -25.51 | -2.86 |
| R&D Expense | 3.83M | - | 5.37M | 2.71M | 5.85M | - | 7.61M | 7.14M | 8.96M | - | 8.45M | 9.06M | 8.37M | - | 11.61M | 8.32M | 9.67M | - | 8.08M | 5.77M | 4.64M | - | 3.26M | 5.52M | 4.51M | 4.96M | 4.13M | 2.37M | 2.65M | 1.89M | 3.44M | 4.17M | 3.86M | 1.89M | - | 1.36M | 1.30M | 925.38K | - | 5.25M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 25.23M | 23.12M | 21.85M | 15.10M |
| Operating Income | -3.17M | -54.87M | -26.11M | -30.19M | -41.17M | -51.73M | -75.87M | 1.85M | - | -25.23M | -23.12M | -21.85M | -15.10M |
| EBITDA | - | - | - | - | - | - | - | - | - | -24.69M | -21.69M | 6.02M | -293.42M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 7.41M | 8.28M | 4.56M | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | -32.11M | -30.01M | 1.44M | -293.42M |
| Tax Provision | - | - | - | - | - | - | - | - | -1.80M | 0 | - | - | - |
| Net Income | -3.26M | -56.90M | -27.08M | -31.05M | -31.52M | -50.17M | -72.18M | 1.94M | - | -32.11M | -30.01M | 1.44M | -293.42M |
| Diluted EPS | - | - | - | - | - | - | -1.85 | 0.05 | - | -6.01 | -4.61 | 0.19 | -34.67 |
| R&D Expense | 708.49K | 42.91M | 18.53M | 20.44M | 30.26M | 34.89M | 58.12M | 22.04M | 32.04M | 14.65M | 12.71M | 11.90M | 5.76M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 29.17M | 68.45M | 82.58M | 132.94M | 183.70M | 139.14M | 77.50M | 57.63M | - | 55.09M | 56.90M | 37.14M | 97.97M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 40.16M | 42.00M | 22.27M | 83.10M |
| Cash & Equivalents | 200.31K | 1.82M | 18.55M | 14.28M | 82.98M | 26.05M | 50.23M | 21.41M | 25.36M | - | 36.09M | 40.91M | 21.36M | 82.30M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 9.00M | 16.95M | 27.26M | 26.96M | 52.10M | 48.87M | 49.72M | 4.96M | - | 75.11M | 85.36M | 62.84M | 238.72M |
| Current Liabilities | - | 1.41M | 3.51M | 5.32M | 9.69M | 6.84M | 3.61M | 6.63M | 3.16M | - | 1.38M | 3.34M | 2.84M | 2.29M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - |
| Total Equity | 19.02K | 20.18M | 51.50M | 55.32M | 105.98M | 131.60M | 90.26M | 27.78M | 52.66M | - | -20.02M | -28.46M | -25.69M | -140.75M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 5.34M | 6.99M | 6.99M | 43.27M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | 3.09M | -41.94M | -43.43M | -33.82M | - | -24.65M | -14.78M | -19.55M | -13.51M |
| Investing Cash Flow | - | - | -107.19M | 69.49M | 14.08M | 24.53M | - | -16.33K | 0 | 0 | 0 |
| Financing Cash Flow | - | - | 47.17M | -3.34M | 525.00K | 13.24M | - | -5 | 19.60M | 0 | 74.45M |
| Capital Expenditure | -3.23K | -45.61K | -52.40K | - | - | - | - | -16.33K | - | - | - |
| Free Cash Flow | - | - | 3.04M | - | - | - | - | -24.66M | -14.78M | -19.55M | -13.51M |
| Net Change in Cash | - | - | - | - | - | - | - | -24.66M | 4.82M | -19.55M | 60.94M |
| Share Buybacks | - | - | 389 | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | -16.2% | -110.5% | -49.0% | -29.3% | -24.0% | -55.6% | -259.8% | 3.7% | - | 160.3% | 105.4% | -5.6% | 208.5% |
| ROCE % | -11.4% | -84.5% | -33.8% | -24.5% | -23.3% | -38.2% | -107.0% | 3.4% | - | -47.0% | -43.2% | -63.7% | -15.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NERV
Minerva Neurosciences (NERV) awards options tied to Phase 3 trial - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOT05yaThCS293VW1XUXZId3dybE1FcjdpSXY4VUFDam9UTjBCcEFaQzB2NHN3RDNmZ1FYME5XVkVEaUdmYmRVbXBpVDg5YkhuWVZKdDFYMnBTemQ2cDc4eHJZU1ZYVk9zeWtKRnRzaDllRkhxeHZ0dWEtaVZzZDdwWjdNeHZDVmxoMThjX3…
Should I buy Minerva Neurosciences (NERV) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE5Fbjd4bEREQlkzMWtqNlEtLUwxZGFhM2VJQTQ3TmtHS0psVWRZUmRGcWpNSDJETHRXWjhMY3pjUGlUREFCSFo5LU1MVTNvRml3MmM3SlhhRWdWeDZxNHZrTkphU19hT0o0a21ZbA?oc=5" target="_blank">Should I buy Minerva …
Minerva Neurosciences Stock (NERV) Opinions on $200M Funding Deal | NERV Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPVVBERVRCVXdmSWtLV3pGNXNwRkpUa3ZVcnZBUUcxaXN3Ty1UMFllelVvd3EzWlBxRVNSS2diLU9ndjZBRTgyT3gxLU5OTW9TQkVoY3JBUGVDdkVNODhlOGdKVDVxR3FkV3lXU0NmZmE0X2tUb2xVakQtbktDVk1MUWtqS1ZGSXY5dzdYbk…
Minerva stock wins New Outperform at Citizens (NERV:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxPMm5YXzRTYzA5OEl3YnJnLUZxenFtYUdYanJ4eHlNZXhFd0JNSmQ5Z29acmhjbHdhTkpYb0lKYnV2Mlc0cjUzbFhVUDl0UmpIbUZmS1VZR28yODhrYWMwM2ZOM2s3V19ZWjhMTmQxcHBaZWxIay03QVNmYUs2NHRyS0dmTVEtWUk?oc=5" …
NERV|Minerva Neurosciences Inc|Price:4.080|Chg%:+0.110 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBMSG9DSVM5VGJtNDVvRXd1YWVSNFdFUjI1bHZVSzFXa1EzUEkxb3NNakhkTHBPWnNRWWJTU1N6Z19LTW5zOVVrb2xaY2E1bVk5dG1ONXl3cno0Y1NEM0tGOVBBRTdQS1ZuRHFXc1lB?oc=5" target="_blank">NERV|Minerva Neuros…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9DVjZwY2JnT0dnc1lvUDhZbThIQVlZdTYyTHcwYklXOUFJUGNsWFAtMmlxUjkyanoyNjV5QWtxUG9kRXMtTlotcDJCdXNoU3Bz?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
NERV — Frequently Asked Questions
What is the current share price of NERV?
As of 2026-08-05 17:25 PDT, NERV trades at $4.35 on NASDAQ/NYSE. Its 52-week range is $1.76 to $8.07.
What is the market capitalisation of NERV?
NERV has a market capitalisation of $188.24M on NASDAQ/NYSE.
What is the P/E ratio of NERV?
NERV trades at a trailing price-to-earnings (P/E) ratio of -0.13. Its price-to-book (P/B) ratio is -1.34.
Is NERV a good stock to buy?
This page provides a data-driven analysis of NERV, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.